Skip to main content

Table 3 Combination therapies in clinical trials

From: Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

Inhibitor

Biomarker

Cancer type

CRC patients enrollment

Phase

NCT number

Status

KRASG12C combinations

AMG 510 and panitumumab and FOLFIRI regimen

KRASG12C mutation

Advanced solid tumors

Enrolled

Ib/II

NCT04185883

Recruiting

AMG 510 and trametinib and panitumumab

KRASG12C mutation

Advanced solid tumors

Enrolled

Ib/II

NCT04185883

Recruiting

AMG 510 and MVASI® (bevacizumab-awwb) and FOLFIRI or FOLFOX regimen

KRASG12C mutation

Advanced solid tumors

Enrolled

Ib/II

NCT04185883

Recruiting

MRTX849 and TN0155

KRASG12C mutation

Advanced solid tumors

Enrolled

II

NCT04330664

Recruiting

MRTX849 and cetuximab

KRASG12C mutation

Advanced or metastatic CRC

Enrolled

III

NCT04793958

Recruiting

MRTX849 and mFOLFOX6 regimen

KRASG12C mutation

Advanced or metastatic CRC

Enrolled

III

NCT04793958

Recruiting

MRTX849 and FOLFIRI regimen

KRASG12C mutation

Advanced or metastatic CRC

Enrolled

III

NCT04793958

Recruiting

SOS inhibitors combinations

BI 1701963 and trametinib

KRAS mutations

Advanced solid tumors

Not mentioned

I

NCT04111458

Recruiting

SHP2 inhibitors combinations

RMC-4630 and LY3214996

KRAS mutations

Advanced or metastatic solid tumors

Enrolled

I

NCT04916236

Not yet recruiting

TNO155 and JDQ443

KRASG12C mutation

Advanced solid tumors

Enrolled

Ib/II

NCT04699188

Recruiting

RAF-MEK-ERK inhibitors combinations

HM95573 and cobimetinib

RAS or RAF mutations

Advanced or metastatic solid tumors

Enrolled

I

NCT03284502

Recruiting

GDC-0994 and cobimetinib

None

Advanced or metastatic solid tumors

Enrolled

Ib

NCT02457793

Completed

MK-8353 and pembrolizumab

None

Advanced solid tumors

Enrolled

Ib

NCT02972034

Active, not recruiting

Cancer vaccines combinations

TG02 and pembrolizumab

KRAS exon 2, codon 12 or 13 mutation

Rectal cancer

Enrolled

I

NCT02933944

Terminated

mRNA-5671 and pembrolizumab

KRASG12D, KRASG12V, KRASG12C, KRASG13D mutation

NSCLC, non-MSI-H CRC, PDAC

Enrolled

I

NCT03948763

Recruiting

  1. Abbreviations: CRC colorectal cancer, NSCLC non-small cell lung cancer, PDAC pancreatic ductal adenocarcinoma, MSI-H microsatellite instability-high, FOLFOX 5-fluorouracil, leucovorin, and oxaliplatin, FOLFIRI: 5-fluorouracil, leucovorin, and irinotecan. Data acquired from ClinicalTrials.gov